News
The 2024 Give to Cure Cancer Year-End Appeal is now underway. This is a chance to make this year’s campaign the most successful ever.
We are proud to report...
With support from loyal donors, excellent progress has been made in these AFCR-funded projects in…
NOTABLE RESEARCH HIGHLIGHTS
AFCR-supported scientists have made remarkable advances in the fight against cancer. Here are some notable research highlights in 2024 supported by your generous donations.
First-in Class Molecular Glue Degraders
Dr. Lily Zou’s research is at the forefront of developing a novel…
Cancer patients and survivors often have fears related to their health, such as recurrence or pending treatment. But the sources of stress and anxiety don’t stop there. Cancer can ignite concerns about family, finances, changes in body image and the challenges of…
The 2024 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by the National Foundation for Cancer Research (NFCR), AIM-HI Accelerator Fund (AIM-HI), and Asian Fund for Cancer Research (AFCR) will be held on October 18th at the National…
AFCR will celebrate its 20 Year Anniversary in 2025. In those 20 years, AFCR has been focused on funding cancer research, especially those cancers prevalent in Asian populations. Here is a snapshot of the research fields we will fund during 2024-2025.
CHANGING THE…
Hong Kong (5 September 2024) – The Asian Fund for Cancer Research Limited (AFCR) is pleased to announce the winners of the 2024 BRACE Award Venture Competition: the First Prize goes to Concarlo Therapeutics, led by Founder and CEO Stacy Blain, Ph.D.,…
The U.S. Chinese Anti-Cancer Association (USCACA) and AFCR are pleased to invite nominations for the USCACA‐AFCR 2024 Young Investigator Awards.
The Awards will recognize 3 to 5 junior Chinese investigators on the basis of significant contributions in Translational or Clinical Cancer Research.
Candidacy…
On 14 June 2024, AFCR is launching our inaugural Day of Giving. This special event aims to spotlight the critical "unmet needs in cancer research and patient care." By generously supporting AFCR, you empower us to drive groundbreaking discoveries in the fight…
The Asian Fund for Cancer Research (AFCR) proudly recognizes the exceptional contributions of Dr. Yung-Chi Cheng, AFCR Scientific Advisory Board Member, and Henry Bronson Professor of Pharmacology and Medicine at Yale University. Dr. Cheng's unwavering commitment over the past thirty years has…
Did you know that there were 9.5 million newly reported cancer cases and 5.8 million cancer-related deaths occurring in Asia in 2020? These numbers are devastating! Even worse, without intervention, the number of new cases in Asia is anticipated to increase to…
HONG KONG – The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition.
AFCR’s BRACE (Bridging Research from Academia to Cancer Entrepreneurship) Award Venture Competition is designed…
The Asian Fund for Cancer Research (AFCR) is thrilled to unveil its fresh brand logo and slogan, marking a pivotal moment in the organization's quest to advance breakthroughs in cancer globally. The redesigned emblem and impactful slogan firmly establish AFCR as a…
Left to right: Prof. Shi-Yong Sun, Prof. Tianzhi Huang, Prof. Lirong Zhang, Prof. Ming Yan, Prof. Qi Zhang, Prof. Yunguang Tong, Prof. Song Xu, Prof. Binghua Jiang, Prof. Xu Qian, Prof. Zigang Dong.
To foster and strengthen collaborations among cancer researchers and…
Sujuan Ba, Ph.D. has been awarded the Leadership Award for Global Advocate of Cancer Research by the Hong Kong Biotechnology Organization (HKBIO) at their BIOHK2023 Conference (13-16 September, Hong Kong Convention and Exhibition Centre). Dr. Ba is the President, CEO and Founder…
Professor Michael Yang Mengsu, Senior Vice-President (Innovation and Enterprise) of CityU (second from right) and Dr Sujuan Ba (second from left) signed the MoU, witnessed by Mr Lester Garson Huang, Council Chairman of CityU (first from right), and Ms Lillian Cheong, Under…